Share Twitter LinkedIn Facebook Email Ezra Cohen, MD of the University of California at San Diego discusses if biomarkers help select patients more or less likely to benefit from agents targeting EGFR in SCCHN at ASTRO Head and Neck Symposium 2016.
ASH 2025 MDS/ALL Highlights: Verona Trial Lessons & CLEVER Pathway | Dr. Jeyakumar Acute Lymphoblastic Leukemia 5 Mins Read
Advancing Acute Lymphoblastic Leukemia Treatment with CAR-T Cells: Insights from Dr. Anjali Advani Acute Lymphoblastic Leukemia 3 Mins Read